Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenerative Medical Technology (RMTG) EBITDA (2018 - 2025)

Historic EBITDA for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$394068.0.

  • Regenerative Medical Technology's EBITDA fell 56862.09% to -$394068.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$122896.0, marking a year-over-year increase of 3420.49%. This contributed to the annual value of $204201.0 for FY2024, which is 14062.38% up from last year.
  • Regenerative Medical Technology's EBITDA amounted to -$394068.0 in Q3 2025, which was down 56862.09% from -$219639.0 recorded in Q2 2025.
  • Regenerative Medical Technology's 5-year EBITDA high stood at $328422.0 for Q4 2024, and its period low was -$9.0 million during Q3 2021.
  • Moreover, its 5-year median value for EBITDA was -$155395.0 (2024), whereas its average is -$739585.2.
  • In the last 5 years, Regenerative Medical Technology's EBITDA tumbled by 1848360.34% in 2021 and then soared by 62493.77% in 2024.
  • Over the past 5 years, Regenerative Medical Technology's EBITDA (Quarter) stood at -$469854.0 in 2021, then crashed by 432.83% to -$2.5 million in 2022, then surged by 97.5% to -$62564.0 in 2023, then soared by 624.94% to $328422.0 in 2024, then tumbled by 219.99% to -$394068.0 in 2025.
  • Its EBITDA stands at -$394068.0 for Q3 2025, versus -$219639.0 for Q2 2025 and $162389.0 for Q1 2025.